337 related articles for article (PubMed ID: 18688283)
1. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
Toyama K; Wulff H; Chandy KG; Azam P; Raman G; Saito T; Fujiwara Y; Mattson DL; Das S; Melvin JE; Pratt PF; Hatoum OA; Gutterman DD; Harder DR; Miura H
J Clin Invest; 2008 Sep; 118(9):3025-37. PubMed ID: 18688283
[TBL] [Abstract][Full Text] [Related]
2. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling.
Bi D; Toyama K; Lemaître V; Takai J; Fan F; Jenkins DP; Wulff H; Gutterman DD; Park F; Miura H
J Biol Chem; 2013 May; 288(22):15843-53. PubMed ID: 23609438
[TBL] [Abstract][Full Text] [Related]
3. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34.
Freise C; Querfeld U
Pharmacol Res; 2014 Jul; 85():6-14. PubMed ID: 24813858
[TBL] [Abstract][Full Text] [Related]
5. Role of KCa3.1 Channels in Macrophage Polarization and Its Relevance in Atherosclerotic Plaque Instability.
Xu R; Li C; Wu Y; Shen L; Ma J; Qian J; Ge J
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):226-236. PubMed ID: 28062499
[TBL] [Abstract][Full Text] [Related]
6. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
7. Voltage dependence of the Ca(2+)-activated K(+) channel K(Ca)3.1 in human erythroleukemia cells.
Stoneking CJ; Shivakumar O; Thomas DN; Colledge WH; Mason MJ
Am J Physiol Cell Physiol; 2013 May; 304(9):C858-72. PubMed ID: 23407879
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Li H; Zhao JL; Zhang YM; Han SX
Clin Exp Hypertens; 2018; 40(4):303-311. PubMed ID: 29388859
[TBL] [Abstract][Full Text] [Related]
10. Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells.
Zhang Y; Feng Y; Chen L; Zhu J
Cell Biochem Biophys; 2015 Jun; 72(2):515-25. PubMed ID: 25608633
[TBL] [Abstract][Full Text] [Related]
11. KCa3.1 modulates neuroblast migration along the rostral migratory stream (RMS) in vivo.
Turner KL; Sontheimer H
Cereb Cortex; 2014 Sep; 24(9):2388-400. PubMed ID: 23585521
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the intermediate-conductance Ca(2+)-activated K+ channel inhibits the angiogenesis induced by epidermal growth factor in the treatment of corneal alkali burn.
Yang H; Li X; Ma J; Lv X; Zhao S; Lang W; Zhang Y
Exp Eye Res; 2013 May; 110():76-87. PubMed ID: 23482085
[TBL] [Abstract][Full Text] [Related]
13. Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.
Chen CL; Liao JW; Hu OY; Pao LH
Arch Toxicol; 2016 Sep; 90(9):2249-2260. PubMed ID: 26438401
[TBL] [Abstract][Full Text] [Related]
14. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
15. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
16. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
[TBL] [Abstract][Full Text] [Related]
17. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to alkalinization-induced vascular calcification in vitro.
Bai Y; Xu J; Yang S; Zhang H; He L; Zhou W; Cheng M; Zhang S
J Clin Lab Anal; 2021 Aug; 35(8):e23854. PubMed ID: 34313357
[TBL] [Abstract][Full Text] [Related]
18. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
19. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.
Zhu YR; Jiang XX; Zhang DM
J Mol Med (Berl); 2019 Sep; 97(9):1219-1229. PubMed ID: 31254004
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress promotes myocardial fibrosis by upregulating K
Wang LP; Fan SJ; Li SM; Wang XJ; Gao JL; Yang XH
Pflugers Arch; 2017 Sep; 469(9):1061-1071. PubMed ID: 28455747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
